Business
-
According to US-based ARS Pharmaceuticals, the company has raised $20 million in Series C financing for clinical development of its ARS-1 epinephrine nasal spray for the treatment of anaphylaxis. The financing round was led by… Read more . . .
-
Canadian life science fund AmorChem has announced the launch of MyX Therapeutics, which will focus on development of drugs formulated with MyX-001 mucoadhesive nanoparticle delivery platform, with a $450,000 seed investment. MyX-001 is based on… Read more . . .
-
Pharmaxis said that its distribution partner Methapharm Inc. has begun selling Pharmaxis’ Aridol mannitol bronchial challenge test kit again in the United States. According to the company, its Sydney, Australia manufacturing facility received FDA approval… Read more . . .
-
Circassia Pharmaceuticals notified AstraZeneca that it will exercise its option to acquire the full US commercial rights to the Tudorza aclidinium DPI, the company said. Circassia acquired US rights to Tudorza and to Duaklir aclidinium/formoterol… Read more . . .
-
Avanir and Optinose have separately announced the termination of the license agreement that gave Avanir the North American rights to develop and commercialize Onzetra Xsail intranasal sumatriptan. The license agreement, which was initially announced in… Read more . . .
-
According to Auris Medical, the FDA has granted orphan drug designation to its intranasal betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS). The company also said that it has signed a letter… Read more . . .
-
Intranasal drug developer Impel NeuroPharma has raised $67.5 million in a Series D financing round led by KKR and Norwest Venture Partners, the company said. Existing investors Vivo Capital, 5AM Ventures and venBio Partners also… Read more . . .
-
Vast Therapeutics (formerly Novoclem) has announced that Shionogi & Co. was the sole investor in a Series A financing round that will fund pre-clinical and Phase 1 development of the company’s dry powder nitric oxide… Read more . . .
-
US Pharmaceutical company Neurelis, which recently submitted an NDA for Valtoco diazepam nasal spray, has acquired Aegis Therapeutics and its Intravail transmucosal absorption technology, a component of the Valtoco formulation. In addition to Intravail, Aegis… Read more . . .
-
Vectura has announced that a Phase 3 study of VR475 budesonide inhalation suspension for the treatment of severe uncontrolled asthma in adult and adolescent patients failed to meet its primary endpoint. As a result, the… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


